Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Inclisiran (Leqvio) vs Rosuvastatin (Crestor): Rosuvastatin (Crestor) has the stronger overall evidence (4.5 vs 4.1/10); they're alternatives for support heart health — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Rosuvastatin (Crestor) wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Too few graded studies
Top outcomes
Verdict
Too few graded studies
Top outcomes
Shared outcomes (3)
Outcomes where both Inclisiran (Leqvio) and Rosuvastatin (Crestor) have evidence — compare verdict strength side-by-side.
284 mg (300 mg inclisiran sodium) by subcutaneous injection administered by a healthcare professional on day 1, again at day 90 (month 3), then every 6 months thereafter. A prescription drug; this is the approved regimen, not a self-directed supplement protocol.
Any time of day
Prefilled subcutaneous injection (inclisiran 284 mg)
5–20 mg once daily (up to 40 mg in selected high-risk patients), titrated to LDL/ApoB targets — under a clinician. A prescription drug; not a self-directed supplement regimen.
Any time of day
Oral tablet (rosuvastatin 5–20 mg)
and 2 more not shown
Weeks to months; sustained
Ongoing
Outcomes trials ongoing
Around each injection
2–4 weeks
Months to years
1–2 years
Throughout use
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol.
The New England journal of medicine (2020) · Rct · n=3178
ORION-10 and ORION-11 randomized, placebo-controlled phase 3 trials in atherosclerotic cardiovascular disease / high risk
Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia.
The New England journal of medicine (2020) · Rct · n=482
ORION-9 randomized, placebo-controlled phase 3 trial in heterozygous familial hypercholesterolemia
Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol.
The New England journal of medicine (2017) · Rct · n=501
ORION-1 phase 2, double-blind, placebo-controlled, multiple-ascending-dose trial
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
The New England journal of medicine (2008) · Rct · n=17802
JUPITER randomized placebo-controlled primary-prevention trial (~17,800 participants with normal LDL but elevated hsCRP)
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.
Lancet (London, England) (2010) · Meta analysis
Meta-analysis of ~170,000 participants across 26 randomized statin trials
Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial.
JAMA (2006) · Open label · n=507
ASTEROID open-label IVUS trial (507 enrolled; 349 with evaluable serial imaging)
Rosuvastatin (Crestor) has a higher evidence score (4.5/10 vs 4.1/10) and wins in 2 of 3 categories.
For support heart health, Rosuvastatin (Crestor) has a higher relevance score (78 vs 70).
No documented interaction was found in the data searched. This does not establish that this exact combination is safe.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.